Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 9Melanoma 4Neoplasms 3Multiple Myeloma 3Skin Neoplasms 2Polycystic Ovary Syndrome 2Venous Thromboembolism 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Stem Cell Transplant Complications 1Skin Toxicity 1Resectable Pancreatic Ductal Adenocarcinoma 1Renal Insufficiency 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Obesity 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Meningioma 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Inflammation 1

Interventions

Dexamethasone 10Bortezomib 7Lenalidomide 4isatuximab 3Calcium Dobesilate 3pomalidomide 2Thalidomide 2Gemcitabine 2Cyclophosphamide 2vinflunine 1melflufen 1glucarpidase 1gallium 68 PSMA-11 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1auricularum 1Tablets 1Ranitidine 1Pluvicto 1L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1Eplerenone 1Doxorubicin 1Diphenhydramine 1Carboplatin 1Bendamustine Hydrochloride 1BHQ880 1Acetaminophen 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Renal Insufficiency × Tablets × Clear all
NCT02045017 2021-08-27

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Celgene

Phase 2 Completed
81 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡